Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Systematic Validation of Novel Lung Cancer Drivers
EF 2018-19
Résumé
Lung cancer is the number one cause of cancer-related deaths. Targeted therapy (“personalized medicine”) fights specific genetic changes that allow a given cancer to exist. This has improved life expectancy for some of those affected. Still, problems remain. Many cancer-causing genetic changes haven’t been discovered, and even target-treatable cancers will eventually become drug-resistant through further changes. Discovery of new drug targets is therefore important to help improve outcomes. Targets can be found by examining the differences in healthy and tumor lung DNA. However, thousands of changes exist in any given tumor. Separating cancer-causing from irrelevant is complex and can dismiss important genes.
We used a genetic technology termed Sleeping Beauty (SB) to discover new cancer-causing genes. In our mouse model, SB randomly inserts itself into various locations in lung DNA, changing nearby genes. Some of these changes promote cancer. Once tumors formed, we could determine genes SB had frequently changed. This provided powerful causal evidence that these genes are important in lung cancer. Many of these genes are known, showing SB’s success. Other genes are new, and their roles in cancer have yet to be determined. My project will aim to confirm the importance of these genes in lung cancer. I will validate about 150 genes found with SB that are consistent with changes in human lung cancer using a gene disruption screen. I will further confirm and characterize overlapping results from these screens in mice and in human cell lines. The results from this study will aid in the development of new therapies and in improving outcomes for people who suffer from this devastating disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406447
Name
Nagelberg Amy L
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Systematic Validation of Novel Lung Cancer Drivers
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cooperating Cancer Drivers; Crispr Screen; Drug Discovery; Epidermal Growth Factor Receptor(Egfr) Cooperation; Insertional Mutagenesis Mouse Model; Lung Cancer Genomics; Sleeping Beauty; Systematic Validation; Targeted Therapy; Tyrosine Kinase Inhibitor (Tki) Resistance
Abstract
Lung cancer is the number one cause of cancer-related deaths. Targeted therapy (“personalized medicine”) fights specific genetic changes that allow a given cancer to exist. This has improved life expectancy for some of those affected. Still, problems remain. Many cancer-causing genetic changes haven’t been discovered, and even target-treatable cancers will eventually become drug-resistant through further changes. Discovery of new drug targets is therefore important to help improve outcomes. Targets can be found by examining the differences in healthy and tumor lung DNA. However, thousands of changes exist in any given tumor. Separating cancer-causing from irrelevant is complex and can dismiss important genes.
We used a genetic technology termed Sleeping Beauty (SB) to discover new cancer-causing genes. In our mouse model, SB randomly inserts itself into various locations in lung DNA, changing nearby genes. Some of these changes promote cancer. Once tumors formed, we could determine genes SB had frequently changed. This provided powerful causal evidence that these genes are important in lung cancer. Many of these genes are known, showing SB’s success. Other genes are new, and their roles in cancer have yet to be determined. My project will aim to confirm the importance of these genes in lung cancer. I will validate about 150 genes found with SB that are consistent with changes in human lung cancer using a gene disruption screen. I will further confirm and characterize overlapping results from these screens in mice and in human cell lines. The results from this study will aid in the development of new therapies and in improving outcomes for people who suffer from this devastating disease.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nagelberg, Amy L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~